Miss Vanessa Orchard
- Affiliate (School of Cardiovascular & Metabolic Health)
The University of Glasgow uses cookies for analytics. Find out more about our Privacy policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
Analytical cookies help us improve our website. We use Google Analytics. All data is anonymised.
Clarity helps us to understand our users’ behaviour by visually representing their clicks, taps and scrolling. All data is anonymised.
Carberry, J. et al. (2024) Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). European Journal of Heart Failure, (doi: 10.1002/ejhf.3560) (Early Online Publication)
Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)
Bradley, C. P. et al. (2023) The coronary microvascular angina cardiovascular magnetic resonance imaging trial: rationale and design. American Heart Journal, 265, pp. 213-224. (doi: 10.1016/j.ahj.2023.08.067) (PMID:37657593)
McCartney, P. J. et al. (2020) Low-dose alteplase during primary percutaneous coronary intervention according to ischemic time. Journal of the American College of Cardiology, 75(12), pp. 1406-1421. (doi: 10.1016/j.jacc.2020.01.041) (PMID:32216909) (PMCID:PMC7109518)
Corcoran, D. et al. (2018) Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 5(2), e000924. (doi: 10.1136/openhrt-2018-000924) (PMID:30687508) (PMCID:PMC6326326)
Carberry, J. et al. (2024) Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS-MI). European Journal of Heart Failure, (doi: 10.1002/ejhf.3560) (Early Online Publication)
Carberry, J. et al. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11(4), pp. 2001-2012. (doi: 10.1002/ehf2.14830) (PMID:38715187) (PMCID:PMC11287338)
Bradley, C. P. et al. (2023) The coronary microvascular angina cardiovascular magnetic resonance imaging trial: rationale and design. American Heart Journal, 265, pp. 213-224. (doi: 10.1016/j.ahj.2023.08.067) (PMID:37657593)
McCartney, P. J. et al. (2020) Low-dose alteplase during primary percutaneous coronary intervention according to ischemic time. Journal of the American College of Cardiology, 75(12), pp. 1406-1421. (doi: 10.1016/j.jacc.2020.01.041) (PMID:32216909) (PMCID:PMC7109518)
Corcoran, D. et al. (2018) Rationale and design of the Coronary Microvascular Angina Cardiac Magnetic Resonance imaging (CorCMR) diagnostic study: the CorMicA CMR sub-study. Open Heart, 5(2), e000924. (doi: 10.1136/openhrt-2018-000924) (PMID:30687508) (PMCID:PMC6326326)